|
|
|
Allergan PLC | 5.500% Mandatory Convertible Preferred Shares, Series A (AGN.PRA)
Prospectus excerpt: Dividends on the Mandatory Convertible Preferred Shares will be payable on a cumulative basis when, as and if declared by our board of directors, or an authorized committee thereof, at an annual rate of 5.500% on the liquidation preference of $1,000.00 per Mandatory Convertible Preferred Share. We may pay declared dividends in cash, by delivery of our ordinary shares or by delivery of any combination of cash and our ordinary shares, as determined by us in our sole discretion, subject to certain limitations, on March 1, June 1, September 1 and December 1 of each year commencing June 1, 2015, to and including March 1, 2018. Full Prospectus PDF », Secondary Prospectus PDF », AGN Page »
Series: | A | Alternate symbology: | AGN-A, AGN-PA, AGNprA | Redeemable?: | Yes | Maturity Date: | 3/1/2018 | Cumulative?: | Yes | Conversion Ratio: | 2.8345 and 3.4722 | Conversion Price: | $288 to $352.80 | Shares Offered: | 4,600,000 | Overallotment: | 460,000 | Liquidation Preference: | $1,000.00 | Original Coupon: | 5.50% | Pay Period: | Quarterly | Pay Dates: | 1-Mar, 1-Jun, 1-Sep, 1-Dec | CDx3 Compliance Rating: |
Learn AGN.PRA's Rating
|
|
Allergan is a pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Co. has three segments: United States Specialized Therapeutics, which includes products within the United States, including Medical Aesthetics, Medical Dermatology Eye Care and Neuroscience and Urology therapeutic products; United States General Medicine, which includes products within the United States that do not fall into the United States Specialized Therapeutics business units, including Central Nervous System; and International, which includes products sold outside the United States. Preferred: AGN.PRA Open the AGN Information Page »
|
|
|
|
|